Participants:18–64 years · 65+ years
Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

HIV infection

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabotegravir

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Registered drugNo placebo

Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Vutrisiran

Contact Research Centre

Bladder cancer recurrent+1

Not recruiting

InvestigationalNo placebo

Study on Mycobacterium Bovis Bacillus Calmette-Guérin for High-risk Non-muscle Invasive Bladder Cancer Patients

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years

Contact Research Centre

Paroxysmal nocturnal haemoglobinuria

Not recruiting

InvestigationalNo placebo

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemdisiran

Contact Research Centre

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemdisiran

Contact Research Centre

Bladder cancer

Not recruiting

InvestigationalNo placebo

Study on UGN-102 (Mitomycin) for Treating Low Grade Non-Muscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Mitomycin

Contact Research Centre

Find therapies in clinical trials near you – page 9

175 trials match your criteria

Rheumatoid arthritis

Study of lutikizumab and ravagalimab in adults with moderate to severe rheumatoid arthritis

Multifocal motor neuropathy

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Chronic myeloid leukaemia

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Breast cancer+1

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Interstitial lung disease+1

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Hormone receptor positive HER2 negative breast cancer

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

HIV infection

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Cardiac amyloidosis

Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

Bladder cancer recurrent+1

Study on Mycobacterium Bovis Bacillus Calmette-Guérin for High-risk Non-muscle Invasive Bladder Cancer Patients

Paroxysmal nocturnal haemoglobinuria

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

Paroxysmal nocturnal haemoglobinuria

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Bladder cancer

Study on UGN-102 (Mitomycin) for Treating Low Grade Non-Muscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.